Brokerages expect Ascendis Pharma A/S (NASDAQ:ASND) to announce $160,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings. The lowest sales estimate is $20,000.00 and the highest is $230,000.00. Ascendis Pharma A/S posted sales of $510,000.00 in the same quarter last year, which would indicate a negative year over year growth rate of 68.6%. The business is expected to report its next earnings results on Thursday, November 15th.
According to Zacks, analysts expect that Ascendis Pharma A/S will report full year sales of $1.02 million for the current fiscal year, with estimates ranging from $100,000.00 to $3.00 million. For the next fiscal year, analysts forecast that the business will post sales of $52.22 million per share, with estimates ranging from $80,000.00 to $156.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Ascendis Pharma A/S.
Several research analysts recently issued reports on the stock. ValuEngine raised shares of Ascendis Pharma A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. Leerink Swann reissued a “market perform” rating and set a $70.00 target price (up from $64.00) on shares of Ascendis Pharma A/S in a research note on Thursday, May 31st. BidaskClub lowered shares of Ascendis Pharma A/S from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 7th. Wells Fargo & Co increased their target price on shares of Ascendis Pharma A/S from $83.00 to $88.00 and gave the stock an “outperform” rating in a research note on Thursday, August 30th. Finally, Wedbush set a $79.00 target price on shares of Ascendis Pharma A/S and gave the stock a “buy” rating in a research note on Thursday, August 30th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Ascendis Pharma A/S currently has an average rating of “Buy” and a consensus price target of $77.25.
Several institutional investors have recently added to or reduced their stakes in ASND. Atria Investments LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $212,000. Quantbot Technologies LP bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $215,000. Kovack Advisors Inc. bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $218,000. Jane Street Group LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $250,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at $255,000. 95.29% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ ASND traded up $3.23 on Friday, hitting $69.15. 159,400 shares of the company were exchanged, compared to its average volume of 152,790. The firm has a market cap of $2.65 billion, a PE ratio of -15.31 and a beta of 0.67. Ascendis Pharma A/S has a 12 month low of $27.74 and a 12 month high of $76.99.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Story: How to Invest in an Index Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.